June 16, 2020 / 8:37 AM / a month ago

BRIEF-2cureX Establishes Collaboration With Scandion Oncology And Erasmus Medical Centre

June 16 (Reuters) - 2cureX AB:

* 2CUREX AB ESTABLISHES COLLABORATION WITH SCANDION ONCOLOGY A/S AND ERASMUS MEDICAL CENTRE, ROTTERDAM, IN DRUG-RESISTANT BREAST CANCER PATIENTS

* 2CUREX AB ESTABLISHES COLLABORATION WITH SCANDION ONCOLOGY A/S AND ERASMUS MEDICAL CENTRE, ROTTERDAM, IN DRUG-RESISTANT BREAST CANCER PATIENTS

* TODAY ANNOUNCES THAT IT TOGETHER WITH SCANDION ONCOLOGY A/S, COPENHAGEN AND ERASMUS MEDICAL CENTRE, ROTTERDAM HAS RECEIVED A GRANT OF 800.000 EUR FROM EUROSTARS

* GRANT WILL BE USED TO STUDY IF SCANDION ONCOLOGY’S DRUG CANDIDATE, SCO -101 CAN OVERCOME RESISTANCE TO ANTIESTROGEN THERAPY IN METASTATIC BREAST CANCER PATIENTS, AND IF 2CUREX’S INDITREAST TEST CAN STRATIFY SUCH PATIENTS BASED ON SCO-101 SENSITIVITY Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below